Carboprost

Summary

Carboprost (CHEMBL1237122) is an approved small-molecule oxytocic (ATC G02AD04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G02AD04
• Clinical trials: 4
• Chemistry: 368.5 Da · C21H36O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1237122
Name	Carboprost
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5281075
ChEBI	CHEBI:3403
ATC	G02AD04
Molecular formula	C21H36O5
Molecular weight	368.5
InChIKey	DLJKPYFALUEJCK-IIELGFQLSA-N

SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O

IUPAC name: (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid

ChEBI definition: Prostaglandin F2α in which the hydrogen at position 15 is substituted by methyl (S configuration). It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.

Pharmacological roles (ChEBI): oxytocic, abortifacient.

Also known as: Carboprost, Hemabate, U-32,921, U-32921, CARBOPROST

Parent form; salt/anhydrous children: CHEMBL1237105

Patent coverage: 427 distinct patent families (1,834 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06285409	Not specified	RECRUITING	Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
NCT00989027	Not specified	COMPLETED	Impact of Uterotonic Agents on Isolated Human Myometrium
NCT01869556	Not specified	COMPLETED	Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress
NCT02861482	Not specified	COMPLETED	Early Usage of Bakri Ballon in Managing Postpartum Hemorrhage

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).